Form 4 for ACRS Aclaris Therapeutics, Inc.
Accepted 2023-08-03 00:00:00 ET · period of report 2023-08-01 · accession 0001209191-23-044445 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-08-03 | 2023-08-01 | ACRS | Manion Douglas J. | Pres, CEO, Dir | M - OptEx | — | +15.6K | 28.4K | +122% | — |
| D | 2023-08-03 | 2023-08-01 | ACRS | Manion Douglas J. | Pres, CEO, Dir | F - Tax | $9.81 | -4,437 | 23.9K | -16% | -$43.5K |
| D | 2023-08-03 | 2023-08-01 | ACRS | Manion Douglas J. | Pres, CEO, Dir | M - OptEx | $0.00 | -15.6K | 46.7K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-01 | M | A | 15,575 | — | 28,375 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| 2 | Common | Common Stock | 2023-08-01 | F | D | 4,437 | $9.81 | 23,938 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2023-08-01 | M | D | 15,575 | $0.00 | 46,725 | D | — · — to — | 15,575 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F3) The shares underlying these restricted stock units vest in four equal annual installments beginning on August 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. |